Biosimilars Podcast: What To Expect When Supreme Court Hears Amgen vs. Sandoz
Executive Summary
Pink Sheet's Brenda Sandburg talks to Prevision Policy’s Kate Rawson about who has the most at stake in the case, the questions she’ll be listening for during oral arguments, and what might be in store from the newest addition to the Supreme Court: Justice Neil Gorsuch.
You may also be interested in...
Ringside For Zarxio At Supreme Court: Biosimilar Stakeholders Line Up
High court set to determine timing of biosimilar marketing and how parties handle patent disputes in Sandoz v. Amgen. Stakeholders say the outcome will impact innovation, access to biosimilars and future litigation.
Pazdur’s Big Moment: ‘Project Odyssey’ Webinar Gives Oncology Chief External Buy-In On His Ideas To Revamp ODAC
OCE Director Richard Pazdur is known for cultivating 'Pazdur moments' during advisory committees when he feels the conversation has gone off track. A recent webinar with ODAC members created a perfect opportunity to promote his agenda.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.